Top

References

References

  1. Impact Rx – March 2018.
  2. Data on file. Results of an independent survey among South African Optometrists’ reflecting 94.3% confidence level of the total population. June 2016.
  3. Data on file. IMS TPM 21L. PREPARAT. CONTACT LENSES. February 2018.

Artelac

  1. Scheuer CA, et al. Retention of conditioning agent hyaluronan on hydrogel contact lenses. Contact Lens & Anterior Eye 2010,33(1S),2-6.
  2. Dry Eye, facts about [NEI Health Information] [Cited 2014 May 12]; Available from URL: https://www.nei.nih.gov/health/dryeye/dryeye.asp.
  3. Bartlett JD, et al. Diagnostic & treatment algorithms for ocular surface disease states. Dry Eye. Part three of an ongoing series. New paradigms in the understanding and management of dry eye. Review of Optometry October 2011:1-12.
  4. Yao W, et al. Dry Eye Syndrome: An update in office management. Am J Med 2011;124:1016-1018.
  5. Dry Eye Syndrome. Available at: http://www.allaboutvision.com/conditions/dryeye.htm. [Accessed May 26, 2014].
  6. Roach, L. Rethinking meibomian gland dysfunction: How to spot it, stage it and treat it. American Academy of Ophthalmology. Available at https://www.aao.org/eyenet/article/rethinking-meibomian-gland-dysfunction-how-to-spot?julyaugust-2011 [Accessed August 1, 2017].
  7. Meibomian Gland Dysfunction and Treatment. American Association for Pediatric Ophthalmology and Strabismus. https://www.aapos.org/terms/conditions/141 [Accessed August 1, 2017].
  8. Zheng X, et al. In vitro efficacy of ocular surface lubricants against dehydration 2013 Sep;32(9):1260-4.
  9. Hyaluronic Acid. Web MD. Available at: http://www.webmd.com/vitamins-supplements/ingredientmono-1062-hyaluronic%20acid.aspx?activeingredientid=1062& [Accessed May 23, 2017].
  10. Reindel W, et al. Meta-analysis of the ocular biocompatibility of a new multipurpose lens care system. Clin Ophthalmol. 2013;7:2051-6.

Eye Nutrition

  1. Yao W, et al. Dry Eye Syndrome: An update in officce management. Am J Med 2011;124:1016-1018.
  2. Bartlett JD, et al. Diagnostic & Treatment Algorithms for Ocular Surface Disease States. Dry Eye. Part three of an ongoing series. New paradigms in the understanding and management of dry eye. Review of Optometry. October 2011:1-12.
  3. Mertzanis P, et al. The relative burden of dry eye in patients’ lives: comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci. 2005 Jan;46(1):46-50.
  4. National Institutes of Health. National Eye Institute website. Facts about age-related macular degeneration. (http://www.nei.nih.gov/health/maculardegen/armd_facts.asp) Accessed May 2, 2011.
  5. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48(3):257–293.
  6. Graham, RH. There’s nothing fi shy about omega-3 fatty acids for dry eye syndrome. Medscape Ophthalmology. Available at http://www.medscape.com/viewarticle/707984_2. [Accessed January 13,2014].
  7. Omega-3 Fatty Acids. Available at: http://umm.edu/health/medical/altmed/supplement/omega3-fatty-acids. [Accessed May 26, 2014].
  8. Rasmussen HM, et al. Nutrients for the aging eye. Clinical Interventions in Aging 2013; 8:741–748.

Biotrue Multipurpose Solution

  1. Data on file. Results of an independent survey among South African Optometrists’ reflecting 94.3% confidence level of the total population. June 2016.
  2. Reindel W, et al. Meta-analysis of the ocular biocompatibility of a new multipurpose lens care system. Clin Ophthalmol. 2013;7:2051-6.
  3. Scheuer CA, et al. Retention of conditioning agent hyaluronan on hydrogel contact lenses. Contact Lens & Anterior Eye 2010,33(1S),2-6.
  4. Zheng X, et al. In vitro efficacy of ocular surface lubricants against dehydration 2013 Sep;32(9):1260-4.

ReNu Multipurpose Solutions

  1. Data on file. IMS TPM 21L. PREPARAT. CONTACT LENSES. February 2018.

Ultra

  1. Results of an online survey with patients that wore their lenses for 7+ days and on average, wore their lenses for 8 or more hours a day (n=485). Survey questions were top 3-box scores (% Strongly Agree, Agree, Slightly Agree) on a 6-point agreement scale, with a margin of error +/- 2.4%

Dry Eye Syndrome

  1. Scheuer CA, et al. Retention of conditioning agent hyaluronan on hydrogel contact lenses. Contact Lens & Anterior Eye 2010,33(1S),2-6.
  2. Zheng X, et al. In vitro efficacy of ocular surface lubricants against dehydration 2013 Sep;32(9):1260-4.
  3. Reindel W, et al. Meta-analysis of the ocular biocompatibility of a new multipurpose lens care system. Clin Ophthalmol. 2013;7:2051-6.
  4. Hyaluronic Acid. Web MD. Available at: http://www.webmd.com/vitamins-supplements/ingredientmono-1062-hyaluronic%20acid.aspx?activeingredientid=1062& [Accessed May 23, 2017].
  5. Impact Rx – December 2017.

Applicant/Distributed by: Soflens(Pty) Ltd. Reg. No.: 1968/011787/07. 254 Hall Street, Centurion. Tel: +27 10 900 1356.

Proprietary name: Artelac® Advanced Lipids Eye Drops. Contains 2 mg carbomer, medium chain triglycerides. Preservative: Cetrimide(10g multi-dose only).

Proprietary name: Artelac® Advanced Eye Gel. Contains 2 mg carbomer, medium chain triglycerides. Preservative: Cetrimide. Proprietary name: Artelac® Intense Rebalance Eye Drops. Contains 0,15% hyaluronic acid (as sodium hyaluronate), 0,5% polyethylene glycol 8000, vitamin B12. Preservative: Oxyd® (a gentle preservative that converts to water, oxygen and salt at the surface of the eye in the 10ml multi-dose unit only).

Proprietary name: Artelac® Splash Eye Drops. Contains 0,24% hyaluronic acid (as sodium hyaluronate) in the 10ml multi-dose unit and 0,2% hyaluronic acid (as sodium hyaluronate)in the single dose units.Both the 10ml multi-dose and single dose units are preservative free.

Proprietary name: Artelac® Moisture Eye Drops. Contains 0,32% hypromellose. Preservative:Cetrimide(10ml multi-dose only).

Proprietary name and dosage form: OcuviteComplete soft gel capsules. Composition: Each soft gel capsule contains fish oil rich in DHA 507,7 mg: of which DHA 180 mg and total omega-3 300mg, Lutein 5 mg, zeaxanthin 1 mg, vitamin C 90 mg, vitamin E 15 mg, zinc 7,5 mg.

Proprietary name and dosage form: OcuviteLutein tablets.Composition:Each tablet contains Lutein 3 mg, Zeaxanthin 0,25 mg,VitaminE 4,4 mg, Vitamin C 30 mg, Zinc 2,5 mg and 10ug Selenium.

Proprietary name:Biotrue® Multi-Purpose Solution. Contains: Hyaluronan, sulfobetaine, poloxamineand preserved with a dual disinfection system (polyaminopropylbiguanide0,00013 % and polyquaternium0,0001 %).

Proprietary name: Easysept™ 3 % Hydrogen Peroxide. Contains: 3 % Hydrogen Peroxide solution with a phosphonicacidstabiliser, sodium chloride and phosphate buffers.

Scheduling status: S0 Proprietary name and dosage form: Bausch & Lomb ReNu® MultiPlusSolution. Composition: Each ml contains Polyaminopropylbiguanide(Dymed™) 0,0010 mg, Hydroxyalkylphosphonate0,30 mg and Disodium edetate(preservative) 0,11 % m/v. Pharmacological classification: A 34 Contact lens solution. Reg. No.: 33/34/0484.

Scheduling status: S0 Proprietary name and dosage form: Bausch & Lomb ReNu® Multi-Purpose Solution. Composition: Each ml contains Polyaminopropylbiguanide(Dymed™) 0,0005 mg and Disodium edetate(preservative) 0,11 % m/v. Pharmacologicalclassification: A 34 Contact lens solution. Reg. No.: X/34/239.

Proprietary name: Boston® Simplus. Contains: Poloxamine, hydroxyalkylphosphonate, boric acid, sodium borate, sodium chloride and hydroxypropylmethylcellulose, Glucamand preserved with chlorhexidine gluconate (0,0003 %) and polyaminopropylbiguanide(0,0005 %).

Proprietary name: Boston® Simplus. Contains: Poloxamine, hydroxyalkylphosphonate, boric acid, sodium borate, sodium chloride and hydroxypropylmethylcellulose, Glucamand preserved with chlorhexidine gluconate (0,0003 %) and polyaminopropylbiguanide(0,0005 %).

Proprietary name: Bausch & Lomb Boston® ADVANCE Cleaner. Contains: Alkylsulphatesurfactant (8,0 % w/v), sodium chloride, sodium phosphate, non ionic alcohol surfactant, silica gel suspension; with titanium dioxide.

Proprietary name: Bausch & Lomb Boston® ADVANCE Conditioning Solution. Contains: Polyaminopropylbiguanide(0,0005 % w/v), chlorhexidine gluconate (0,003 % w/v), disodium edetate(0,05 % w/v), polyquaternium10, cellulosic viscosifier, polyvinyl alcohol and derivatisedpolyethylene glycol.

For full prescribing information, refer to the package insert as approved by the MCC (Medicines Control Council) professional information or instructions for use. Further information is available on request from Bausch + Lomb.